Has Benjamin Garmezy, MD received payments from drug or device companies?

Yes. Drug and device makers reported $8,365,480 in general payments to Benjamin Garmezy, MD across 1,800 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Benjamin Garmezy, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Benjamin Garmezy, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Benjamin Garmezy, MD

Hematology & Oncology · Nashville, TNNPI 1770961617

Payments from drug & device makers

$8,365,480in general payments, 2019–2025

Across 1,800 payments — averaging $4647.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Exelixis Inc.$2.3M
Genentech, Inc.$999K
Janssen Research & Development, LLC$902K
AbbVie$678K
AVEO Pharmaceuticals, Inc.$585K
Takeda Pharmaceuticals U.S.A., Inc.$569K
plus $2.3M from 54 others

$12,226in research payments, 2019–2025

Across 17 payments — averaging $719.17 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Pfizer$10K
F. Hoffmann-la Roche AG$1K
Amgen$582
Novartis$238

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Exelixis Inc.	416	$2,295,721
Genentech, Inc.	199	$999,143
Janssen Research & Development, LLC	143	$901,896
AbbVie	190	$678,207
AVEO Pharmaceuticals, Inc.	255	$584,547
Takeda Pharmaceuticals U.S.A., Inc.	98	$569,033
Eli Lilly	5	$528,028
Astrazeneca UK Limited	8	$368,035
Pfizer	61	$297,756
Amgen	8	$294,384
Novartis	30	$292,634
GSK	17	$154,569
Merck	33	$134,499
AstraZeneca(2 entities)	37	$133,269
E.r. Squibb & Sons, L.L.C.	43	$43,714
Bayer	30	$30,512
Daiichi Sankyo Inc.	28	$25,329
Eisai Inc.	25	$10,168
Biontech SE	2	$8,706
Seagen Inc.	3	$4,496
EMD Serono, Inc.	7	$2,500
Janssen Scientific Affairs, LLC	6	$2,141
Johnson & Johnson	17	$1,622
Sanofi	12	$1,268
Gilead	10	$459
Regeneron Healthcare Solutions, Inc.	17	$344
Telix Pharmaceuticals	2	$267
Galvanize Therapeutics, Inc	1	$214
Genentech USA, Inc.	10	$205
Array Biopharma Inc	6	$126
Lilly USA, LLC	6	$123
Jazz Pharmaceuticals Inc.	5	$116
Ferring Pharmaceuticals Inc.	1	$112
Bristol Myers Squibb	6	$106
Astellas Pharma US Inc	4	$86
Tersera Therapeutics LLC	5	$83
Beigene USA, Inc.	4	$80
Genmab U.S., Inc.	3	$71
Springworks Therapeutics, Inc.	3	$65
Caris MPI, Inc.	4	$64
Mirati Therapeutics, Inc.	3	$58
Servier Pharmaceuticals LLC	3	$58
Stemline Therapeutics Inc.	2	$50
Coherus Oncology, Inc.	3	$49
Tempus AI, Inc	2	$47
Iovance Biotherapeutics, Inc.	2	$43
Boehringer Ingelheim	2	$37
Pharmaessentia USA Corporation	2	$37
Sun Pharmaceutical Industries Inc.	2	$37
Incyte Corporation	2	$33
Sumitomo Pharma America, Inc.	2	$28
Pharmacyclics LLC, An Abbvie Company	1	$25
Cumberland Pharmaceuticals, Inc.	1	$24
Deciphera Pharmaceuticals Inc.	1	$22
Beone Medicines USA, Inc.	1	$22
Verity Pharmaceuticals Inc.	1	$21
Rigel Pharmaceuticals, Inc.	1	$21
Ipsen Biopharmaceuticals, Inc	1	$21
Karyopharm Therapeutics Inc.	1	$21
Puma Biotechnology, Inc.	1	$21

How this compares

$8,365,480 in reported general payments places this provider in the 95th percentile of 251 hematology & oncology providers in Tennessee.

See all hematology & oncology providers in Tennessee →

Medicare billing

Part B allowed, 2024

$1,489,823

Medicare patients

278

Services billed

44,261

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Nashville

Erika HamiltonNashville$45.4M
Ian FlinnNashville$41.2M
Johanna BendellNashville$28.5M
Jesus BerdejaNashville$22.2M
Meredith McKeanNashville$16M
Krish PatelNashville$14.2M
Denise YardleyNashville$13.2M
Todd BauerNashville$10.9M
Wade IamsNashville$8.9M
Brian RiniNashville$8.1M

See the full list for Tennessee →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →